GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Total Payout Ratio

Everest Medicines (HKSE:01952) Total Payout Ratio : 0.04 (As of Jun. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Everest Medicines's current Total Payout Ratio is 0.04.

Everest Medicines Total Payout Ratio Historical Data

The historical data trend for Everest Medicines's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Total Payout Ratio Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
Get a 7-Day Free Trial - 0.60 -0.05 0.02 0.04

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - -0.01 0.04 0.03

Competitive Comparison of Everest Medicines's Total Payout Ratio

For the Biotechnology subindustry, Everest Medicines's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Total Payout Ratio falls into.


Everest Medicines Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Everest Medicines's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 32.58 + 0) / -923.656
=0.04

Everest Medicines's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 14.024 + 0) / -460.318
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Total Payout Ratio
Comparable Companies
HKSE:02105 HKSE:06660 HKSE:02315 HKSE:06955 HKSE:09966 HKSE:06855 HKSE:01541 HKSE:02696 HKSE:02480 HKSE:00775 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
6HN:Germany
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Website
https://www.everestmedicines.com
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Ra Capital Management, L.p. 2102 Investment manager
Kolchinsky Peter 2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Fu Wei 2307 Founder of a discretionary trust who can infl
Janchor Partners Limited 2102 Investment manager
C-bridge Capital Gp, Ltd. 2501 Other
Vistra Trust (singapore) Pte. Limited 2501 Other
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited 2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines